Shots:
The Board of Directors has decided to cease the P-IIb (PARADIGME) trial, following a thorough examination and independent data evaluation of (PARADIGME) trial and a subsequent request for regulatory agency interaction. There will be no more patients enrolled in the trial
Betalutin has continued to exhibit an appealing safety profile and positive signs of efficacy in some patients at a dose of 15 MBq/kg after a pre-dose of 40mg lilotomab while the observed profile does not fully meet the objectives set out for (PARADIGME) study
The Board has also agreed to immediately begin reorganizing the company to lower expenses to support essential activities related to pipeline development
Ref: PRNewswire | Image: Nordic Nanovector
